EPOPROSTENOL Drug Patent Profile
✉ Email this page to a colleague
When do Epoprostenol patents expire, and what generic alternatives are available?
Epoprostenol is a drug marketed by Gland, Meitheal, Mylan, and Sun Pharm. and is included in four NDAs.
The generic ingredient in EPOPROSTENOL is epoprostenol sodium. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Epoprostenol
A generic version of EPOPROSTENOL was approved as epoprostenol sodium by MEITHEAL on April 23rd, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EPOPROSTENOL?
- What are the global sales for EPOPROSTENOL?
- What is Average Wholesale Price for EPOPROSTENOL?
Summary for EPOPROSTENOL
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Drug Prices: | Drug price information for EPOPROSTENOL |
| DailyMed Link: | EPOPROSTENOL at DailyMed |
US Patents and Regulatory Information for EPOPROSTENOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gland | EPOPROSTENOL SODIUM | epoprostenol sodium | INJECTABLE;INJECTION | 219237-001 | Dec 29, 2025 | AP2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | EPOPROSTENOL SODIUM | epoprostenol sodium | INJECTABLE;INJECTION | 210473-001 | Jan 15, 2021 | AP2 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Meitheal | EPOPROSTENOL SODIUM | epoprostenol sodium | INJECTABLE;INJECTION | 078396-002 | Apr 23, 2008 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm | EPOPROSTENOL SODIUM | epoprostenol sodium | INJECTABLE;INJECTION | 210473-002 | Jan 15, 2021 | AP2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Gland | EPOPROSTENOL SODIUM | epoprostenol sodium | INJECTABLE;INJECTION | 219237-002 | Dec 29, 2025 | AP2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Meitheal | EPOPROSTENOL SODIUM | epoprostenol sodium | INJECTABLE;INJECTION | 078396-001 | Apr 23, 2008 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan | EPOPROSTENOL SODIUM | epoprostenol sodium | INJECTABLE;INJECTION | 213913-002 | Jun 12, 2024 | AP2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
